Lecap Asset Management Ltd. Decreases Stake in Azenta, Inc. $AZTA

Lecap Asset Management Ltd. reduced its position in Azenta, Inc. (NASDAQ:AZTA) by 31.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,304 shares of the company’s stock after selling 6,005 shares during the period. Lecap Asset Management Ltd.’s holdings in Azenta were worth $409,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in shares of Azenta by 788.1% in the first quarter. Farther Finance Advisors LLC now owns 968 shares of the company’s stock worth $33,000 after buying an additional 859 shares in the last quarter. State of Wyoming lifted its position in shares of Azenta by 77.1% in the first quarter. State of Wyoming now owns 2,343 shares of the company’s stock worth $81,000 after buying an additional 1,020 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Azenta by 13,184.2% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,524 shares of the company’s stock worth $87,000 after buying an additional 2,505 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Azenta by 83.6% in the second quarter. GAMMA Investing LLC now owns 3,446 shares of the company’s stock worth $106,000 after buying an additional 1,569 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Azenta by 41.5% in the first quarter. Quarry LP now owns 3,120 shares of the company’s stock worth $108,000 after buying an additional 915 shares in the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $32.45 on Friday. The business’s 50 day moving average price is $30.39 and its 200-day moving average price is $30.01. Azenta, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $55.63. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -13.41 and a beta of 1.62.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The firm had revenue of $143.94 million for the quarter, compared to the consensus estimate of $149.64 million. During the same period in the prior year, the business posted $0.14 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Sell-side analysts predict that Azenta, Inc. will post 0.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZTA has been the topic of a number of research analyst reports. Raymond James Financial upgraded Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 target price on the stock in a research report on Wednesday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Azenta in a research report on Saturday, September 27th. Stephens initiated coverage on Azenta in a research report on Tuesday, July 22nd. They set an “equal weight” rating and a $35.00 price objective on the stock. Finally, Evercore ISI set a $33.00 price objective on Azenta and gave the company an “in-line” rating in a research report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $35.75.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.